Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
2025 · 3rd Quarter (July 1 - Sep 30)
ALNYLAM PHARMACEUTICALS, INC.
Filed by CAPITOL COUNSEL LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 15, 2025
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- CAPITOL COUNSEL LLC
- Filing UUID
- a48c52fc-d7fa-4ee5-abc0-84c11e631f7f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.